Revenue Performance - Net revenues increased to $28.0 million, a rise of $21.3 million or 318% compared to $6.7 million in the same period last year[136]. - Net revenues for the Audio Segment rose to $13.7 million in Q1 2025, up from $6.7 million in Q1 2024, reflecting a $7.0 million increase[149]. - The Video Segment reported net revenues of $14.3 million in Q1 2025, with operating expenses of $18.1 million, resulting in a segment operating loss of $3.8 million[150]. - Spot Radio & TV Advertising accounted for 57% of total net revenues, while Digital revenues surged to 34% of total net revenues[128]. Operating Performance - Operating loss for the three months ended March 31, 2025, was $4.7 million, an increase of $1.2 million or 35% from a loss of $3.5 million in the prior year[136]. - Adjusted EBITDA for the three months ended March 31, 2025, was $1.4 million, reflecting a 55% increase from $0.9 million in the same period last year[136]. - Adjusted EBITDA for Q1 2025 was $1.4 million, compared to $0.9 million in Q1 2024, indicating improved operational performance[152]. Expenses - Operating expenses increased to $29.2 million, up $22.6 million or 340% from $6.7 million in the prior year[138]. - Corporate expenses decreased to $1.6 million, down $1.8 million or 53% from $3.4 million in the previous year[138]. - Operating expenses related to Corporate and other decreased to $1.6 million in Q1 2025 from $3.4 million in Q1 2024, due to lower professional service fees[151]. Cash Flow and Liquidity - Cash flows from operating activities rose by $1.6 million, or 399%, to $2.1 million compared to $0.4 million in the prior year[136]. - Cash flows provided by operating activities increased to $2.1 million in Q1 2025, compared to $0.4 million in Q1 2024, primarily due to increased deferred revenue[156]. - The company had cash, cash equivalents, and restricted cash of $8.8 million as of March 31, 2025, up from $6.9 million at the end of 2024[154]. - The company anticipates meeting its liquidity needs for the next twelve months through cash on hand and projected cash flows from operations[153]. Losses - Net loss increased to $8.6 million, up $4.9 million or 134% from a net loss of $3.7 million during the same period last year[136]. - Consolidated net loss increased to $8.6 million for the three months ended March 31, 2025, compared to a net loss of $3.7 million in the same period of 2024[148]. Interest Expense - Interest expense increased to $3.8 million, up $3.6 million from $0.1 million in the prior year, reflecting the impact of rising interest rates[138]. - Interest expense increased to $3.8 million in Q1 2025, attributed to additional long-term debt from the Estrella Acquisition[145]. Acquisition Impact - The Estrella Acquisition in April 2024 significantly contributed to the increase in both net revenues and operating expenses[139][140]. Working Capital - Negative working capital increased to $22.3 million as of March 31, 2025, compared to $18.0 million at the end of 2024, driven by increased accounts payable and accrued expenses[154].

Revenue Performance - Revenues from continuing operations increased by 276% from $127,000 in Q1 2024 to $477,000 in Q1 2025[111] - Revenues from discontinued operations decreased by 24% from $444,000 in Q1 2024 to $339,000 in Q1 2025[115] - The company recorded $326 in IT Services Revenues from related-party transactions during the three months ended March 31, 2025[145] - No revenues were recorded in discontinued operations for two agreements with Everli S.p.A. during the three months ended March 31, 2025[144] Expense Management - Total operating expenses decreased by 52% from $1,405,000 in Q1 2024 to $675,000 in Q1 2025[106] - Cost of revenues from continuing operations increased by 85% from $175,000 in Q1 2024 to $323,000 in Q1 2025[118] - Cost of revenues from discontinued operations decreased by 92% from $908,000 in Q1 2024 to $73,000 in Q1 2025[119] - General and administrative expenses from continuing operations decreased by 71% from $1,230,000 in Q1 2024 to $352,000 in Q1 2025[121] - Interest expenses, net from continuing operations decreased by 78% from $806,000 in Q1 2024 to $179,000 in Q1 2025[125] Financial Position - Net loss from continuing operations improved from $3,410,000 in Q1 2024 to $378,000 in Q1 2025, a reduction of 89%[107] - As of March 31, 2025, the company had cash and cash equivalents of $100[130] - Financial liabilities increased by 4% or $851 from $23,851 as of December 31, 2024, to $24,702 as of March 31, 2025[135] - The company has a total of $10,612 in current financial liabilities from continuing operations as of March 31, 2025[134] Business Strategy - The company entered into Securities Purchase Agreements to sell its mobility and media businesses due to high costs and cash burn[100] - The company shifted its core business focus from micromobility and media services to software services in 2024[98] - The company plans to continue funding operations and expansion through debt and equity financing over the next twelve months[131] Legal and Compliance - The company is in default for non-payment under the terms of several loans, including a judgment for approximately $2,454 related to an unsecured loan[136] - The company entered into a Stock Purchase Agreement with Palella Holdings LLC to sell 100% of the equity interest of European entities, pending court approval[140] - As of March 31, 2025, the company had total outstanding securities of 92,214,637 common shares and 3,712 warrants, restricted stocks, and stock options[138] - The company has the right to sell up to $25 million of its shares under a Standby Equity Purchase Agreement with YA II PN, Ltd[130]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39136 micromobility.com, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organ ...

Revenue and Growth - Revenue growth rates for fiscal years 2024 and 2025 were 13% and 20% respectively, indicating a potential decline in future growth [84]. - The company expects to invest heavily in growth, which may lead to increased sales and marketing, research and development expenses, and declining margins [86]. - The company must continually attract new customers and reduce non-renewals to grow its business, as many customers do not enter long-term contracts [94]. - The company has a limited operating history, making it difficult to predict future operating results and increasing investment risk [88]. - Market opportunity estimates and growth forecasts are subject to significant uncertainty, and even if markets grow, the company may not achieve similar growth rates [113]. - The anticipated benefits from growth initiatives and operating plans are based on assumptions that may prove inaccurate, potentially impacting the company's financial results [155]. Customer Concentration and Risks - The revenue is concentrated within a small number of key customers, with no single customer accounting for 10% or more of total revenue for the fiscal years ended March 31, 2025, 2024, and 2023 [97]. - The company relies on a limited number of customers and agencies for a significant portion of its revenue, increasing credit risk if their financial conditions decline [100]. - Economic conditions, including inflation and potential recessions, may lead customers to reduce spending on the company's solutions [96]. - The loss of significant pharmaceutical brands could adversely affect revenue and relationships with customers [110]. Competition and Market Position - The company anticipates increasing competition in the market for its solutions, particularly from larger established companies and emerging smaller firms [101]. - The company competes for marketing, hiring, and IT budgets from pharmaceutical and health system companies, facing competition from both online and offline organizations [102]. - Maintaining and enhancing brand recognition is critical for attracting new customers and retaining existing ones, with potential substantial investments required [103]. - The company’s "physicians first" philosophy may lead to decisions that prioritize member interests over immediate financial gains, potentially impacting revenue [104]. Operational Challenges - The company faces significant challenges in managing growth, which could negatively impact its reputation and operating results [85]. - The company faces challenges in maintaining its corporate culture amid rapid growth and remote work, which could impact innovation and employee retention [108]. - The company may experience fluctuations in tax obligations and effective tax rates due to changes in tax laws and regulations, which could materially affect results of operations [140]. - The company incurs significant expenses related to being a public company, which may divert management's focus from growth strategies [180]. Compliance and Regulatory Risks - The company faces potential compliance costs and regulatory actions due to proposed or enacted laws governing AI development and use, which may impact service offerings and business efficiency [123]. - Significant resources may be required to ensure compliance with various data protection requirements, which could fundamentally affect business activities and result in material harm [124]. - The evolving regulatory landscape may increase operational costs and affect the company's financial results [216]. - The company faces risks related to compliance with federal and state healthcare laws, which could lead to significant penalties if not adhered to [209]. Intellectual Property and Technology - The company may face challenges in protecting its intellectual property from unauthorized use, which could harm its brand and business [184]. - The company has not yet obtained any issued patents that provide protection for its technology or products, and pending patent applications may not result in issued patents [190]. - The company relies on trade secrets and confidentiality agreements to protect its proprietary information, but these measures may not be fully effective [197]. - The integration of third-party technologies poses risks, including potential inability to generate sufficient revenue to offset acquisition and maintenance costs [162]. Financial Position and Market Risks - The company had cash and cash equivalents of $209.6 million and marketable securities of $706.1 million as of March 31, 2025, compared to $96.8 million and $666.1 million, respectively, as of March 31, 2024 [332]. - A hypothetical 100 basis point increase in interest rates would have resulted in a decrease of $5.4 million in the market value of cash equivalents and marketable securities as of March 31, 2025 [333]. - The company is exposed to market risks from interest rate changes, which may affect interest income and the fair value of investments [332]. - The dual class common stock structure allows certain affiliates to significantly influence corporate matters, limiting stockholder control [231]. Strategic Relationships and Acquisitions - The company has completed acquisitions, including Curative Talent in fiscal 2021 and AMiON in fiscal 2023, and may pursue further acquisitions to enhance capabilities and expand market reach [148]. - The company depends on strategic relationships with third parties for growth, and failure to maintain these relationships could impair its competitive position [159]. - The company may need to obtain additional licenses for technology and data used in its applications, and restrictions on these licenses could adversely affect its operations [160]. Miscellaneous Risks - The company's platform is vulnerable to cybersecurity threats, which could lead to unauthorized access, data loss, and significant financial implications [125]. - The company may incur substantial damages and penalties for noncompliance with communication laws, such as the Telephone Consumer Protection Act (TCPA), which could adversely affect business operations [136]. - The company may face significant litigation costs and potential judgments that could adversely affect its financial condition and results of operations [145]. - The company may experience disruptions from pandemics or other catastrophic events, affecting its operations and financial results [169][171].

Revenue Performance - Revenue for Q1 2025 was $2.0 million, a decrease of 25% from $2.7 million in Q1 2024, primarily due to a decrease in total average enrolled members[157]. - Total revenue decreased by $0.7 million, or 25%, to $2.017 million for the three months ended March 31, 2025, compared to $2.680 million in the same period of 2024[169]. Operating Expenses and Losses - Total operating expenses for Q1 2025 were $6.6 million, up from $6.0 million in Q1 2024, with increases in research and development and general administrative expenses[168]. - Total operating expenses increased by $0.6 million, or 10%, to $6.596 million for the three months ended March 31, 2025, compared to $5.978 million in 2024[172]. - Operating loss for Q1 2025 was $(5.9) million, compared to $(4.3) million in Q1 2024, indicating a worsening financial performance[168]. - Operating loss increased by $1.577 million, or 37%, to $5.850 million for the three months ended March 31, 2025[172]. Net Loss and Financial Challenges - Net loss for Q1 2025 was $(6.9) million, compared to $(4.5) million in Q1 2024, reflecting increased operational challenges[168]. - Interest expense, net increased by $858,000, or 469%, to $(183,000) for the three months ended March 31, 2025, compared to $(1.041 million) in 2024[174]. - The company is not in compliance with the consolidated liquidity or consolidated recurring revenue covenants as of March 31, 2025[178]. Cash Flow and Liquidity - Cash flow from operations improved to $(2.7) million in Q1 2025 from $(3.3) million in Q1 2024, attributed to increased collections on accounts receivable and efficient cash flow management[158]. - Net cash used in operating activities was $2.723 million for the three months ended March 31, 2025, an improvement from $3.259 million in 2024[181]. - Total cash as of March 31, 2025, was $4.1 million, with negative working capital of approximately $3.1 million[175]. Member Enrollment and Programs - Callable outreach pool for WholeHealth+ increased by 45% to 7,319 members as of March 31, 2025, compared to 5,057 members in the same period last year[159]. - Callable outreach pool for Ontrak Engage program reached 22,152 members as of March 31, 2025, reflecting the program's launch on an à la carte basis in early 2024[160]. - A health plan customer notified the company of its intent to discontinue services after December 2024, leading to disenrollment of related members[152]. - The company aims to increase eligible members by signing new contracts and identifying more eligible members within existing contracts[161]. Debt and Financing - The company entered into an agreement with Acuitas to purchase up to $5.0 million in principal amount of Demand Notes and senior secured non-convertible promissory notes[153]. - The company had $13.5 million of secured debt outstanding as of March 31, 2025, with additional borrowing of $0.5 million under the Keep Well Agreement on May 9, 2025[176]. Cost of Revenue and Gross Profit - Cost of revenue increased by $0.3 million, or 30%, to $1.271 million for the three months ended March 31, 2025, compared to $0.975 million in 2024[170]. - Gross profit decreased by $1.0 million to $746,000, with a gross profit margin decline of 27% to 37% for the three months ended March 31, 2025[171].

Revenue Performance - Revenue for Q1 2025 was $2.0 million, a decrease of 25% from $2.7 million in Q1 2024, primarily due to a decrease in total average enrolled members[157] - Total revenue decreased by $0.7 million, or 25%, to $2.017 million for the three months ended March 31, 2025, compared to $2.680 million in the same period of 2024[169] Operating Expenses and Loss - Total operating expenses for Q1 2025 were $6.6 million, up from $6.0 million in Q1 2024, with increases in research and development and general administrative expenses[168] - Total operating expenses increased by $0.6 million, or 10%, to $6.596 million for the three months ended March 31, 2025, driven by increases in research and development and general and administrative costs[172] - Operating loss for Q1 2025 was $(5.9) million, compared to $(4.3) million in Q1 2024, indicating a worsening financial performance[168] - Operating loss increased by $1.577 million, or 37%, to $5.850 million for the three months ended March 31, 2025[172] Cash Flow and Liquidity - Cash flow from operations improved to $(2.7) million in Q1 2025 from $(3.3) million in Q1 2024, attributed to increased collections on accounts receivable and efficient cash flow management[158] - Net cash used in operating activities improved to $2.723 million for the three months ended March 31, 2025, compared to $3.259 million in the same period of 2024[181] - Total cash as of March 31, 2025, was $4.1 million, with negative working capital of approximately $3.1 million[175] - The company was not in compliance with consolidated liquidity or consolidated recurring revenue covenants as of March 31, 2025, raising substantial doubt about its ability to continue as a going concern[178] Member Enrollment and Outreach - Callable outreach pool for WholeHealth+ increased by 45% to 7,319 members as of March 31, 2025, compared to 5,057 members a year earlier[159] - Callable outreach pool for Ontrak Engage reached 22,152 members as of March 31, 2025, reflecting the program's launch on an à la carte basis in early 2024[160] - The company aims to increase eligible members by signing new contracts and identifying more eligible members within existing contracts[161] Debt and Financing - The company entered into an agreement with Acuitas to purchase up to $5.0 million in Demand Notes and $5.0 million in senior secured non-convertible promissory notes[153] - Interest expense, net increased by $858,000, or 469%, to $183,000 for the three months ended March 31, 2025, due to a higher average total outstanding loan balance[174] - The company had $13.5 million of secured debt outstanding as of March 31, 2025, with additional borrowing of $0.5 million under the Keep Well Agreement on May 9, 2025[176] Customer Relations - A health plan customer notified the company of its intent to discontinue services after December 2024, leading to disenrollment of related members[152] - The company has a minimum guarantee of $5.8 million over a two-year period with a customer, extended to June 30, 2025, with $4.6 million invoiced as of March 31, 2025[163] Cost of Revenue and Profitability - Cost of revenue increased by $0.3 million, or 30%, to $1.271 million for the three months ended March 31, 2025, primarily due to higher employee compensation and benefit costs[170] - Gross profit decreased by $1.0 million to $746,000, with gross profit margin declining by 27% to 37% for the three months ended March 31, 2025[171]

Financial Performance - Total revenue for Q4 2024 was $29.1 million, a 41% increase compared to $20.6 million in Q4 2023[6] - Annual Recurring Revenue (ARR) at the end of Q4 2024 was $99.4 million, up 39% from $71.3 million in Q4 2023[6] - Total revenue for the full year 2024 was $103.9 million, a 31% increase from $79.6 million in 2023[6] - Total revenue for the nine months ended September 30, 2024 was $74.8 million, a 27% increase compared to $59.0 million in the same period of 2023[5] - Total revenue for the twelve months ended December 31, 2024, was $74,765,000, representing a 26.7% increase from $58,985,000 in 2023[23] Profitability Metrics - Adjusted EBITDA for Q4 2024 was $0.4 million, compared to a loss of $(10.3) million in Q4 2023[6] - The company achieved positive adjusted EBITDA in Q4 2024, six months ahead of schedule[2] - Gross profit for the year ended December 31, 2024, was $59.3 million, compared to $31.9 million for the previous year, representing an 86.1% increase[17] - The total comprehensive loss for the year was $54.0 million, compared to $108.1 million in the previous year, indicating a significant reduction[18] - Adjusted gross profit for the twelve months ended December 31, 2024, reached $64,100 million, up from $34,462 million in 2023, reflecting an 85.8% year-over-year growth[33] Net Loss and Earnings Per Share - Net loss for the full year 2024 was $(54.0) million, or $(0.34) per share, compared to $(108.0) million, or $(0.72) per share in 2023[6] - The net loss for Q4 2024 was $15.7 million, a slight improvement from a net loss of $17.2 million in Q4 2023[17] - Net loss for the twelve months ended December 31, 2024, was $54.02 million, improved from $108.05 million in the previous year[37] - Adjusted loss per share for Q4 2024 was $0.03, compared to $0.08 in Q4 2023, indicating a reduction in losses[37] Cash and Liquidity - As of December 31, 2024, the company had cash and cash equivalents of $51.9 million and no debt[6] - Cash and cash equivalents decreased to $37,015,000 at the end of 2024 from $67,162,000 at the end of 2023, reflecting a decrease of 44.7%[22] - Cash flows from operating activities showed a net cash used of $34,057 million for the nine months ended September 30, 2024, compared to $6,658 million for the same period in 2023[27] Expenses - Research and development expenses for the year totaled $23.4 million, a decrease from $24.5 million in the previous year[17] - Sales and marketing expenses increased to $61.3 million for the year, compared to $55.0 million in 2023, reflecting a 9.4% rise[17] - One-time employee separation costs for the three months ended December 31, 2024, amounted to $2,060 million, compared to $262 million in the same period of 2023[34] - Stock-based compensation for the twelve months ended December 31, 2024, totaled $24,756 million, slightly increasing from $24,129 million in 2023[36] Customer Metrics - The company reported a total of 60 new customers in Q3 2024, compared to 52 in Q2 2024, indicating a growth in customer acquisition[29] - Total net units shipped rose from 375 in Q1 2024 to 468 in Q3 2024, indicating an increase of 24.8%[29] Future Outlook - The company plans to continue focusing on cost management and operational efficiency to improve future performance[37]

Exhibit 99.1 Keysight Technologies Reports Second Quarter 2025 Results Achieves above guidance results, full-year outlook improved SANTA ROSA, Calif., May 20, 2025 - Keysight Technologies, Inc. (NYSE: KEYS) today reported financial results for the second fiscal quarter ended April 30, 2025. "Keysight delivered strong second quarter results with revenue and earnings per share above the high end of guidance. This quarter's performance underscores the strength of our long-term strategy, deep customer engagemen ...

Exhibit 99.1 Palo Alto Networks Reports Fiscal Third Quarter 2025 Financial Results SANTA CLARA, Calif., May 20, 2025 — Palo Alto Networks (NASDAQ: PANW), the global cybersecurity leader, announced today financial results for its fiscal third quarter 2025, ended April 30, 2025. Total revenue for the fiscal third quarter 2025 grew 15% year over year to $2.3 billion, compared with total revenue of $2.0 billion for the fiscal third quarter 2024. GAAP net income for the fiscal third quarter 2025 was $0.3 billio ...

Financial Performance - For the three months ended March 31, 2025, net revenue was $1.4 million, a decrease of 41.7% from $2.4 million for the same period in 2024[184]. - Gross margin profit for the three months ended March 31, 2025 was $0.5 million, compared to a gross margin loss of $0.1 million for the same period in 2024, resulting in an overall gross margin of 36.8%[186]. - Net loss from continuing operations for the three months ended March 31, 2025 was $4.7 million, or $(0.13) per share, compared to a net loss of $5.5 million, or $(0.32) per share, for the same period in 2024[190]. - Adjusted EBITDA from continuing operations for the three months ended March 31, 2025, was $(1,614,000), an improvement from $(4,286,000) in the prior year[196]. Revenue Generation - The company did not generate any revenues from diagnostic services for the three months ended March 31, 2025 and 2024, respectively[184]. - The company has not provided any diagnostic services since 2024 due to a significant decrease in demand and reimbursement rates[180]. - The company has not generated any diagnostic services revenue from the HRSA funding program for the three months ended March 31, 2025[213]. Expenses and Costs - General and administration expenses decreased by $3.2 million to $4.1 million for the three months ended March 31, 2025, compared to $7.3 million for the same period in 2024[187]. - Research and development costs decreased to $97,000 for the three months ended March 31, 2025, down from $272,000 for the same period in 2024, reflecting reduced activities related to product research[188]. - Interest expense increased to $539,000 for the three months ended March 31, 2025, compared to $441,000 for the same period in 2024, due to a higher balance of outstanding debt[189]. - The company incurred $4,000,000 in cash used in operating activities during the three months ended March 31, 2025[197]. - The Company anticipates that increased costs for retail operations due to inflation will be passed on to customers, while costs related to diagnostic services will be absorbed by the Company[219]. Cash and Capital - As of March 31, 2025, the company's cash and cash equivalents totaled $88,000, a significant decrease from $678,000 at December 31, 2024[197]. - The company anticipates continuing to incur losses and will require additional capital to fund operations, which may be raised through public or private equity or debt financings[202]. - The company sold 1,033,500 shares of common stock in April 2024, generating cash proceeds of $4,600,000 after offering costs[217]. - The Company closed a public offering selling 4,795,000 shares at $0.72 per share, raising gross proceeds of $3.5 million and net cash proceeds of $3.0 million after offering costs[218]. Obligations and Agreements - The company has a royalty obligation of 5.5% on sales of Equivir products following the first commercial sale[203]. - Under the Linebacker License Agreement, the company is required to pay $900,000 upon achieving a first Phase 3 study and an additional $1,000,000 upon receiving regulatory approval for the first product[204]. - The company has a term note agreement with an implicit interest rate of 15% for cash proceeds of $500,000, requiring monthly interest payments[212]. Market Conditions and Risks - Current economic conditions may lead to a decline in business and consumer spending, adversely affecting the Company's financial performance[225]. - The Company does not expect material losses in its investment portfolio or excessive exposure to market risks associated with interest rates[224]. - The Company has not experienced material changes in market risk exposures since December 31, 2024[226]. - There were no material changes in critical accounting estimates or accounting policies from December 31, 2024[221]. Strategic Initiatives - The company continues to actively pursue acquisition opportunities for other companies, technologies, and products within and outside the consumer products industry[182]. - The company acquired exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test and related intellectual property assets in January 2023[175].